Drug intelligence / Profile preview

anti-SARS-CoV-2 polyclonal immunoglobulin

Development stage: Phase 2
Lead developer: Kamada
Modality: Antibody-Based Therapeutics
Administration: Intravenous

Overview

Anti-SARS-CoV-2 polyclonal immunoglobulin is a human plasma-derived immunoglobulin G (IgG) product developed as a treatment for COVID-19 patients. It is designed to provide passive immunity against the SARS-CoV-2 virus. The product is being developed through a global collaboration between Kamada and Kedrion Biopharma. Kamada is responsible for product development, manufacturing, clinical development, regulatory submissions, and distribution in certain territories, while Kedrion Biopharma provides plasma from recovered donors and handles commercialization in other regions. The initial focus for patient access is in Italy, Israel, and the U.S. through clinical programs.

Other names: human plasma-derived Anti-SARS-CoV-2 polyclonal immunoglobulin (IgG) product

Targets

S1-NTD (SARS-CoV-2 spike S1 N-terminal domain)RBD (SARS-CoV-2 spike receptor-binding domain)S2 (SARS-CoV-2 spike S2 subunit)

Beyond the preview

Go deeper on anti-SARS-CoV-2 polyclonal immunoglobulin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-SARS-CoV-2 polyclonal immunoglobulin.

Explore the full profile